{
    "nct_id": "NCT03406156",
    "official_title": "A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy",
    "inclusion_criteria": "* Adequate hematology, kidney and liver function as described in the protocol\n* Diagnosis of previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) according to 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-sponsored Working Group (IWCLL NCI-WG) criteria\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0 - 1\n* CLL/SLL requires treatment according to the IWCLL criteria\n* Medium tumor burden (any lymph node [LN] 5 to < 10 cm OR absolute lymphocyte count [ALC] ≥ 25 × 10^9/L) OR High tumor burden (any LN ≥ 10 cm OR ALC ≥ 25 × 10^9/L and LN ≥ 5 cm)\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Presence of 17p deletion at Screening\n* Richter's syndrome (transformation of CLL/SLL to aggressive non-Hodgkin's lymphoma or Hodgkin's lymphoma)\n* Prolymphocytic leukemia",
    "miscellaneous_criteria": ""
}